Lung Cancer Screening and Staging

Lung cancer screening and staging are two linked tasks in pulmonary oncology: screening uses low-dose computed tomography to detect cancer earlier in people at high risk, while staging uses the TNM system to summarize how far a diagnosed tumor has spread. Together they shape when lung cancer is found and how its extent is described.

Definition

Lung cancer screening is the systematic use of low-dose CT to detect lung cancer in asymptomatic high-risk individuals, while staging is the classification of a diagnosed lung cancer's anatomic extent using the TNM system (tumor, node, metastasis).

Scope

This topic explains the rationale and evidence for low-dose CT screening of high-risk populations and the structure of TNM staging maintained by the IASLC. It treats both as reference methods for early detection and disease description, not as individualized clinical guidance or eligibility advice.

Key concepts

• Low-dose computed tomography (LDCT)
• High-risk eligibility (age and smoking history)
• Mortality reduction as the screening endpoint
• False positives and overdiagnosis
• TNM classification (tumor, node, metastasis)
• IASLC/UICC stage groupings
• Clinical versus pathologic staging

Mechanisms

Screening works by imaging asymptomatic high-risk people with low-dose CT to detect tumors at an earlier, more treatable stage; randomized trials have shown that this lowers lung cancer mortality relative to no screening or chest radiography, at the cost of false-positive findings and some overdiagnosis. Staging, by contrast, characterizes an already-diagnosed tumor: the TNM system codes the size and local extent of the primary tumor (T), the involvement of regional lymph nodes (N), and the presence of distant metastasis (M), which are combined into stage groupings that summarize prognosis. The IASLC periodically revises these groupings using large international datasets.

Clinical relevance

Familiarity with screening evidence and TNM staging is fundamental to interpreting lung cancer literature and understanding how the disease is detected and described. This entry summarizes methods and evidence; it does not provide individual screening eligibility, diagnostic, or treatment recommendations.

Epidemiology

Because lung cancer is common and usually diagnosed late, screening high-risk populations and accurately staging disease are central to efforts to reduce its mortality; the major trials enrolled older participants with substantial smoking histories, the population in which screening benefit has been demonstrated.

History

Low-dose CT screening moved from concept to evidence-based practice after the National Lung Screening Trial reported a lung cancer mortality reduction in 2011, with the European NELSON trial later providing further randomized support in 2020 and bodies such as the US Preventive Services Task Force issuing screening recommendations. In parallel, the TNM staging system for lung cancer has been refined through successive editions led by the IASLC staging project.

Debates

Balancing benefit against harm in lung cancer screening

Randomized trials show that low-dose CT screening reduces lung cancer mortality in high-risk groups, but false-positive findings, downstream procedures, and overdiagnosis temper the net benefit and continue to shape who is offered screening.

Seminal works

• nlst-2011
• de-koning-2020
• goldstraw-2016

Frequently asked questions

Who is screening for lung cancer intended for?

Screening trials and recommendations target asymptomatic adults at high risk on the basis of age and a substantial smoking history; this entry describes that evidence in general terms and is not a source of individual eligibility advice.

What do the T, N, and M categories mean in lung cancer staging?

T describes the size and local extent of the primary tumor, N describes the involvement of regional lymph nodes, and M describes the presence of distant metastasis; combined, they define the stage grouping that summarizes how far the cancer has spread.